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Fig. 1. IL28B genotype concordance between donor PBMC and post-LT liver
biopsies.
Letters to the EditorWe read with interest the article by Coto-Llerena et al. [1] show-
ing that the determination of the donor interleukin 28B (IL28B)
genotype on post-liver transplantation (LT) graft biopsies carries
a high risk of misclassiﬁcation, as it adds to the current debate on
the clinical role of this test in LT patients. Indeed, following LT it
is still somewhat unclear whether the donor, the recipient or the
combination of the two IL28B genotypes is actually associated
with the achievement of a sustained virological response (SVR)
after interferon (IFN)-based treatment in HCV patients [2–6].
Clearing this matter would have important clinical implications,
especially since IL28B genotyping of the recipient can be easily
performed by DNA extraction from the blood, while on the other
hand, given that donor blood is not always routinely available for
clinical use, donor DNA needs to be extracted from formalin-ﬁxed
parafﬁn embedded (FFPE) liver tissue specimens obtained before,
during or after LT. Although this is feasible from a technical
standpoint, no study has shown whether the IL28B genotype
obtained matches that obtained from peripheral blood mononu-
clear cells (PBMC). For this matter, the authors analyzed the IL28B
rs12979860 donor genotype, by TaqMan real-time PCR and direct
sequencing, in 56 HCV-infected LT recipients and their donors, in
PBMCs and/or liver biopsies obtained at the moment of LT (reper-
fusion) or at any time during post-transplant follow-up. Overall,
IL28B rs12979860 genotyping was successful in up to 98% of sam-
ples. The authors report a 100% match in IL28B genotype between
donor PBMC and reperfusion biopsies in 36 out of 56 patients
studied, while, they found a high rate of discordant results
between IL28B genotype in donor PBMC or reperfusion liver biop-
sies compared to post-transplant liver biopsy specimens. To
externally validate these ﬁndings, we analyzed the IL28B geno-
type of 39 liver donors by comparing DNA extracted from donor
PBMC and FFPE or snap frozen post-transplant follow-up liver
biopsies. IL28B rs12979860 genotyping was performed by Taq-
Man real-time PCR, and conﬁrmed by Tetra-primers Ampliﬁca-
tion Refractory Mutation System (T-ARMS) PCR [7]. As shown
in Fig. 1, we replicate Coto-Llerena’s ﬁndings, since overall in
39% of cases there was a mismatch between IL28B genotype
obtained in PBMCs and post-LT liver biopsies. Moreover, similar
mismatch rates were found when IL28B genotype was tested
from DNA extracted from snap frozen or FFPE follow-up liver
biopsies (36% vs. 45%, p = 0.55). Our data therefore show that,
independently from the source used to extract DNA, the use of
follow-up biopsies should be discouraged as a routine test to
determine donor IL28B genotype due to an extremely high mis-
match rate.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
Alessio Aghemo
First Division of Gastroenterology,
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
via Sforza, 35, 20122 Milano,
Italy⇑Corresponding author. Tel.: +39 02 55035432;
fax: +39 02 50320410
E-mail address: Francesca.donato@policlinico.mi.it (M.F. Donato)
1422 Journal of Hepatology 2012 vol. 56 j 1420–1429
